Nuveen’s Idexx Laboratories IDXX Stock Holding History

Nuveen’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,500	Closed	-$4K	–	3365
2022 Q1	$4K	Buy	+7,500	New	+$3.95M	﹤0.01%	3342

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Nuveen's IDXX Position: Q2 2026 in Review

Nuveen increased its Idexx Laboratories (IDXX) stake by 8.7% in Q2 2026, buying an estimated $21.7M and bringing the position to 484,519 shares worth $255M. The position accounts for 0.06% of the portfolio, ranked #235.

Nuveen first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $396M in Q2 2021. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Nuveen held 484,519 shares of Idexx Laboratories worth $255M as of Q2 2026.
Nuveen bought 38,715 Idexx Laboratories shares in Q2 2026, an estimated $21.7M.
Idexx Laboratories made up 0.06% of Nuveen's portfolio in Q2 2026, its #235 holding.
Nuveen first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
Nuveen's Idexx Laboratories position peaked at $396M in Q2 2021.
1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.